<DOC>
	<DOC>NCT02220907</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.</brief_summary>
	<brief_title>Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Men or women age ≥20 years old HbA1c of ≥7.0% and &lt;10.5% FPG of ≤ 270 mg/dL Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before treatment period Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes Patients with serious diabetic complications Patients with hereditary glucosegalactose malabsorption or primary renal glucosuria Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification Patients with severe hepatic disorder or severe renal disorder.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MT-2412</keyword>
	<keyword>MP-513</keyword>
	<keyword>TA-7284</keyword>
	<keyword>Teneligliptin</keyword>
	<keyword>Canagliflozin</keyword>
</DOC>